Valproic acid (VPA) inhibits the epithelial–mesenchymal transition in prostate carcinoma via the dual suppression of SMAD4

Journal of Cancer Research and Clinical Oncology

Volumn 142, Issue 1, 2016, Pages 177-185

  Lan, Xiaopeng ^a   Lu, Guoliang ^a   Yuan, Chuanwei ^a   Mao, Shaowei ^a   Jiang, Wei ^b   Chen, Yougen ^a   Jin, Xunbo ^a   Xia, Qinghua ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b DONGYING PEOPLE S HOSPITAL   (China)

Author keywords

Epithelial mesenchymal transition; Prostate carcinoma; SMAD4; Valproic acid

Indexed keywords

ANTICONVULSIVE AGENT; MESSENGER RNA; SMAD4 PROTEIN; SMAD4 PROTEIN, HUMAN; SMALL INTERFERING RNA; VALPROIC ACID;

ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BAGG ALBINO MOUSE; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; ENZYME IMMUNOASSAY; EPITHELIAL MESENCHYMAL TRANSITION; GENETICS; HUMAN; IMMUNOPRECIPITATION; MALE; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; PROSTATIC NEOPLASMS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; ANTICONVULSANTS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SMAD4 PROTEIN; TUMOR CELLS, CULTURED; VALPROIC ACID; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84953639392     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-015-2020-4     Document Type: Article

References (43)

1. Abend A, Kehat I (2015) Histone deacetylases as therapeutic targets—from cancer to cardiac disease. Pharmacol Ther 147C:55–62
2. Axelrod H, Pienta KJ (2014) Axl as a mediator of cellular growth and survival. Oncotarget 5(19):8188–8852
3. Bruzzese F, Leone A, Rocco M, Carbone C, Piro G, Caraglia M, Di Gennaro E, Budillon A (2011) HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J Cell Physiol 226(9):2378–2390
4. Chang CC, Hsu WH, Wang CC, Chou CH, Kuo MY, Lin BR, Chen ST, Tai SK, Kuo ML, Yang MH (2013) Connective tissue growth factor activates pluripotency genes and mesenchymal–epithelial transition in head and neck cancer cells. Cancer Res 73(13):4147–4157
5. Chiu CT, Wang Z, Hunsberger JG, Chuang DM (2013) Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev 65(1):105–142
6. Choi JY, Kim JH, Jo SA (2014) Acetylation regulates the stability of glutamate carboxypeptidase II protein in human astrocytes. Biochemical and biophysical research communications 450(1):372–377
7. Cincarova L, Zdrahal Z, Fajkus J (2013) New perspectives of valproic acid in clinical practice. Expert Opin Investig Drugs 22:1535–1547
8. Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J, Perry SR, Labrot ES, Wu X, Lis R, Hoshida Y, Hiller D, Hu B, Jiang S, Zheng H, Stegh AH, Scott KL, Signoretti S, Bardeesy N, Wang YA, Hill DE, Golub TR, Stampfer MJ, Wong WH, Loda M, Mucci L, Chin L, DePinho RA (2011) SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 470(7333):269–273
9. Drabsch Y, ten Dijke P (2012) TGF-beta signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev 31(3–4):553–568
10. Dupont S, Mamidi A, Cordenonsi M, Montagner M, Zacchigna L, Adorno M, Martello G, Stinchfield MJ, Soligo S, Morsut L, Inui M, Moro S, Modena N, Argenton F, Newfeld SJ, Piccolo S (2009) FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell 136(1):123–135
11. Dupont S, Inui M, Newfeld SJ (2012) Regulation of TGF-beta signal transduction by mono- and deubiquitylation of Smads. FEBS Lett 586(14):1913–1920
12. Falkenberg KJ, Johnstone RW (2014) Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 13(9):673–691
13. Fattet L, Ay AS, Bonneau B, Jallades L, Mikaelian I, Treilleux I, Gillet G, Hesling C, Rimokh R (2013) TIF1gamma requires sumoylation to exert its repressive activity on TGFbeta signaling. J Cell Sci 126(Pt 16):3713–3723
14. Fuxe J, Vincent T, Herreros AG (2010) Transcriptional crosstalk between TGF-β and stem cell pathways in tumor cell invasion: role of EMT promoting Smad complexes. Cell Cycle 9(12):2363–2374
15. Han RF, Li K, Yang ZS, Chen ZG, Yang WC (2014) Trichostatin A induces mesenchymal-like morphological change and gene expression but inhibits migration and colony formation in human cancer cells. Mol Med Rep 10(6):3211–3216
16. He Y, Huang C, Sun X, Long XR, Lv XW, Li J (2012) MicroRNA-146a modulates TGF-beta1-induced hepatic stellate cell proliferation by targeting SMAD4. Cell Signal 24(10):1923–1930
17. Hesling C, Fattet L, Teyre G, Jury D, Gonzalo P, Lopez J, Vanbelle C, Morel AP, Gillet G, Mikaelian I, Rimokh R (2011) Antagonistic regulation of EMT by TIF1gamma and Smad4 in mammary epithelial cells. EMBO Rep 12(7):665–672
18. Hudak L, Tezeeh P, Wedel S, Makarevic J, Juengel E, Tsaur I, Bartsch G, Wiesner C, Haferkamp A, Blaheta RA (2012) Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion. Prostate 72(16):1719–1735
19. Jiang W, Zheng Y, Huang Z, Wang M, Zhang Y, Wang Z, Jin X, Xia Q (2014) Role of SMAD4 in the mechanism of valproic acid’s inhibitory effect on prostate cancer cell invasiveness. Int Urol Nephrol 46(5):941–946
20. Kalluri R, Weinberg RA (2009) The basics of epithelial–mesenchymal transition. J Clin Investig 119(6):1420–1428
21. Khanim FL, Bradbury CA, Arrazi J, Hayden RE, Rye A, Basu S, MacWhannell A, Sawers A, Griffiths M, Cook M, Freeman S, Nightingale KP, Grimwade D, Falciani F, Turner BM, Bunce CM, Craddock C (2009) Elevated FOSB-expression; a potential marker of valproate sensitivity in AML. Br J Haematol 144(3):332–341
22. Kortenhorst MS, Isharwal S, van Diest PJ, Chowdhury WH, Marlow C, Carducci MA et al (2009) Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo. Mol Cancer Ther 8(4):802–808
23. Kotiyal S, Bhattacharya S (2014) Breast cancer stem cells, EMT and therapeutic targets. Biochem Biophys Res Commun 453(1):112–116
24. Kwon KJ, Kim JN, Kim MK, Kim SY, Cho KS, Jeon SJ, Kim HY, Ryu JH, Han SY, Cheong JH, Ignarro LJ, Han SH, Shin CY (2013) Neuroprotective effects of valproic acid against hemin toxicity: possible involvement of the down-regulation of heme oxygenase-1 by regulating ubiquitin–proteasomal pathway. Neurochem Int 62(3):240–250
25. Li GF, Qian TL, Li GS, Yang CX, Qin M, Huang J, Sun M, Han YQ (2012) Sodium valproate inhibits MDA-MB-231 breast cancer cell migration by upregulating NM23H1 expression. Genet Mol Res 11(1):77–86
26. Li P, Yang R, Gao WQ (2014) Contributions of epithelial–mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer. Mol Cancer 13:55
27. Martin SK, Kamelgarn M, Kyprianou N (2014) Cytoskeleton targeting value in prostate cancer treatment. Am J Clin Exp Urol 2(1):15–26
28. Omer D, Harari-Steinberg O, Buzhor E, Metsuyanim S, Pleniceanu O, Zundelevich A, Gal-Yam EN, Dekel B (2013) Chromatin-modifying agents reactivate embryonic renal stem/progenitor genes in human adult kidney epithelial cells but abrogate dedifferentiation and stemness. Cell Reprogram 15(4):281–292
29. Roca H, Hernandez J, Weidner S, McEachin RC, Fuller D, Sud S et al (2013) Transcription factors OVOL1 and OVOL2 induce the mesenchymal to epithelial transition in human cancer. PLoS ONE 8(10):e76773
30. Saylor PJ, Armstrong AJ, Fizazi K, Freedland S, Saad F, Smith MR, Tombal B, Pienta K (2013) New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol 63(2):309–320
31. Shan Z, Feng-Nian R, Jie G, Ting Z (2012) Effects of valproic acid on proliferation, apoptosis, angiogenesis and metastasis of ovarian cancer in vitro and in vivo. Asian Pac J Cancer Prev 13(8):3977–3982
32. Shimmi O, Newfeld SJ (2013) New insights into extracellular and post-translational regulation of TGF-beta family signalling pathways. J Biochem 154(1):11–19
33. Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):5–29
34. Slingerland M, Guchelaar HJ, Gelderblom H (2014) Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors. Anticancer Drugs 25(2):140–149
35. Srivastava RK, Kurzrock R, Shankar S (2010) MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial–mesenchymal transition in vivo. Mol Cancer Ther 9(12):3254–3266
36. Takai N, Desmond JC, Kumagai T, Gui D, Said JW, Whittaker S, Miyakawa I, Phillip Koeffler H (2004) Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res 10:1141–1149
37. Talmadge JE, Fidler IJ (2010) AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res 70(14):5649–5669
38. Tsai C, Leslie JS, Franko-Tobin LG, Prasnal MC, Yang T, Mackey LV, Fuselier JA, Coy DH, Liu M, Yu C, Sun L (2013) Valproic acid suppresses cervical cancer tumor progression possibly via activating Notch1 signaling and enhances receptor-targeted cancer chemotherapeutic via activating somatostatin receptor type II. Arch Gynecol Obstet 288(2):393–400
39. Wang Y, Zhou BP (2011) Epithelial-mesenchymal transition in breast cancer progression and metastasis. Chin J Cancer 30(9):603–611
40. Wedel S, Hudak L, Seibel JM, Makarevic J, Juengel E, Tsaur I, Wiesner C, Haferkamp A, Blaheta RA (2011) Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells. Clin Exp Metastasis 28(5):479–491
41. Xie F, Zhang Z, van Dam H, Zhang L, Zhou F (2014) Regulation of TGF-beta superfamily signaling by SMAD mono-ubiquitination. Cells 3(4):981–993
42. Yao D, Dai C, Peng S (2011) Mechanism of the mesenchymal–epithelial transition and its relationship with metastatic tumor formation. Mol Cancer Res 9(12):1608–1620
43. Zhu ML, Kyprianou N (2010) Role of androgens and the androgen receptor in epithelial–mesenchymal transition and invasion of prostate cancer cells. FASEB J 24(3):769–777